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Abstract
Currently, effective and specific diagnostic imaging of brain glioma is a major challenge. Nanomedicine plays an essential
role by delivering the contrast agent in a targeted manner to specific tumor cells, leading to improvement in accurate
diagnosis by good visualization and specific demonstration of tumor cells. This study investigated the preparation and
characterization of a targeted MR contrast agent, transferrin-conjugated superparamagnetic iron oxide nanoparticles (Tf-
SPIONs), for brain glioma detection. MR imaging showed the obvious contrast change of brain glioma before and after
administration of Tf-SPIONs in C6 glioma rat model in vivo on T2 weighted imaging. Significant contrast enhancement of
brain glioma could still be clearly seen even 48 h post injection, due to the retention of Tf-SPIONs in cytoplasm of tumor
cells which was proved by Prussian blue staining. Thus, these results suggest that Tf-SPIONs could be a potential targeting
MR contrast agent for the brain glioma.
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Introduction
Magnetic resonance imaging(MRI) is currently the preferred
method in clinical diagnosis of brain glioma, with the character-
istics of non-invasive, high spatial resolution, multi-direction,
multi-sequence and multi-parameter imaging capability [1].
Current approach for diagnosis and grading of brain glioma is
utilizing MR imaging with administration of gadolinium chelate-
based contrast agents [2]. However, gadolinium chelate-based
contrast agents suffer issues of short imaging time, fast diffusion,
and certain side effects in patients, especially of nonspecifically
targeting brain glioma [3,4]. Developing a novel contrast agent
which can overcome these limitations has currently become a
challenge. Superparamagnetic iron oxide nanoparticles (SPIONs)
have recently emerged as magnetic nanocrystals which have been
explored preclinically for their ability to aid in brain tumor
visualization on MRI [5,6]. SPIONs not only have high relaxation
rate but also display outstanding biocompatibility, biodegradability
and nontoxicity [7]. SPIONs, however, have no specificity to
target brain glioma [8]. Nanoparticles’ surface modified with
specific ligands, can improve the contrast enhancement effect of
tissue on MRI [9,10]. Furthermore, till now, there are only limited
examples of SPIONs successful for glioma on MRI [11,12]. Since
targeting ligands plays a crucial role in detection of brain tumor,
developing a specific MRI contrast agent conjugated with a target-
specific ligand for brain glioma would add to the current avenue
for glioma diagnosis.
Transferrin (Tf) is a single-chain glycoprotein containing about
700 amino acids, and belongs to the transferrin family [13]. Tf is
one of the most widely used tumor targeting ligand since tumor
cells express Tf receptors (TfRs) more commonly than other
general cells [14]. Not only does Tf bind to TfRs with high affinity
but the receptors are found to be overexpressed in several human
carcinomas including breast, ovary, and brain cancers such as
glioma and glioblastomas [15,16,17]. These findings make the
transferrin family potentially valuable as cancer biomarkers.
Besides, transferrin receptor-mediated endocytosis of transferrin-
bound iron complexes has been stated as one of the most
characteristic processes in cell biology [13,18]. Furthermore,
owing to the TfRs existing on the blood-brain barrier (BBB),
conjugation of transferrin with a contrast agent, e.g. SPIONS, may
allow Tf to circumvent the impermeable barrier, be readily
delivered to brain, and concomitantly enhancing their role as a
carrier [19,20]. In view of developing a multifunctional contrast
agent, TfRs deserve particular mention for embodying an
important target for glioma therapy, as they have the ability to
downregulate neural tumor cell cycles and glioma expansion [16].
Thus, all these factors indicate that Tf conjugated SPIONs (Tf-
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agents in targeting brain glioma. Although lactoferrin(Lf) which
belongs to the transferrin family, offers a useful new tool as a brain
glioma biomarker, it has not been widely used or translated for use
in medical imaging, and part of the reason being the lack of
lactoferrin receptors monoclonal antibodies. Thus, the probes (Tf-
SPIONs) represent potentially valuable new imaging tools for
application to a number of clinically relevant diseases that involve
Tf receptors overexpression.
In this study, we aim to determine: firstly, the development and
characterization of Tf-SPIONs as well as whether it is suitable for
MR imaging; secondly, whether Tf-SPIONs could be specifically
and efficiently internalized by C6 glioma cells and detected by MR
imaging; and thirdly, whether Tf-SPIONs could act as a specific
targeting MRI contrast agent for brain glioma in vivo without
saturation of the TfRs on BBB.
Results
Characterization of Tf-SPIONs
SPIONs surface chemistry and Tf conjugation were confirmed
by FTIR. Fig. 1 shows the FTIR spectra of SPIONs (blue curve)
and Tf-SPIONs (red curve). The results showed that peaks at
about 630, 590 and 450 cm
21 both from SPIONs (blue curve) and
Tf-SPIONs (red curve) were typical Fe-O absorption bands. After
conjugation with Tf, amide I band peak around 1696 cm
21 and
amide II band peak around 1653 cm
21 were observed, as
represented by the red curve of Fig. 1.
The morphology and size distribution of SPIONs and Tf-
SPIONs by TEM images were shown in Fig. 2. The morphology
of Tf-SPIONs was similar to SPIONs. The average particle size
calculated from the statistical analysis of SPIONs was
9.360.5 nm, and Tf-SPIONs average particle size was
14.160.6 nm.
The T2 relaxation time was the linear fit with the particle
concentration. When the Tf-SPIONs concentration increased, the
signal intensity decreased (Fig. 3a). The T2 relaxivity coefficient
value (1/T2, S
21) of Tf-SPIONs from the MRI was
64.3 S
21 mM
21 (Fig. 3b). This is suggestive of their prospective
use as a negative MRI contrast agent in T2-weighted imaging.
In vitro Study
MR T2-weighted images of the nanoparticles cultured with C6
cells of various concentrations are shown in Fig. 4a. Cells treated
with Tf-SPIONs showed a significant negative contrast enhance-
ment at each of the nanoparticle concentrations, compared to the
tumor cells incubated with bare SPIONs. The signal enhancement
displayed in the cells cultured with Tf-SPIONs is consistent with
the cellular uptake studies. The iron absorbed by C6 cells
incubated with Tf-SPIONs was much higher than cells incubated
with SPIONs at different nanoparticle concentrations (Fig. 4b).
This result demonstrated that, C6 cells could efficiently and
specifically internalize Tf-SPIONs compared to SPIONs.
After Prussian blue staining, Tf-SPIONs and SPIONs were both
found in the cytoplasm of C6 cells and appeared as blue spots. C6
cells incubated with Tf-SPIONs (Figure 5b) contained large
amount of blue spots in the cytoplasm, whereas only a few blue
particles were observed in the cytoplasm of C6 cells cultured with
SPIONs (Figure 5c).
In vivo Study
To verify whether Tf-SPIONs could act as a specific targeting
MRI contrast agent for brain tumor, we performed MR imaging
with male Wistar rat brain glioma models (n=16) in vivo and
compared with the resulting findings following administration of
Tf-SPIONs and SPIONs. Fig. 6 showed the MR imaging of rat
brain tumor, after intravenous injection with SPIONs or Tf-
SPIONs as a contrast agent at the dose of 12 mg Fe/kg. The T2-
Figure 1. Fourier transform infrared spectroscopy spectra of SPIONs (blue curve) and Tf-SPIONs (red curve), respectively.
doi:10.1371/journal.pone.0037376.g001
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2 h, 24 h and 48 h post-injection exhibited a region of apparent
hypointensity compared to the baseline on T2-weighted images
(Fig. 6). The hypointense region within the glioma lesion is
indicative of nanoparticle accumulation, which causes reduction in
signal intensity on T2-weighted images. After injection of Tf-
SPIONs, the MR signal intensity at the tumor site decreased by
32%–65% in comparison to the preinjection image of tumor, and
the area of signal change of the tumor increased gradually until
48 h (Fig. 6). Conversely, the post-injection images of rat
administrated with SPIONs showed almost no signal reduction
within the tumor tissue.
Finally, to confirm that the signal intensity change of tumor
following administration of Tf-SPIONs was due to the accumu-
lation of Tf-SPIONs in the tumor tissue, rather than gadolinium
chelate-based contrast agents or SPIONs which were trapped in
the tumor vascularity, we performed the Prussian blue staining of
the tumor tissue species after the MR imaging. Prussian blue
staining demonstrated the accumulation of Tf-SPIONs in the
tumor tissue up to 48 h after the injection (Fig. 7). Tf-SPIONs
were found to be located in the cytoplasm of the tumor cells, and
consequently this accumulation manifested as reduction in signal
intensity on T2-weighted images of brain glioma as shown in
Fig. 6. Concurrently, Prussian blue staining proved negative in
tumor-bearing rats with SPIONs.
Discussion
In this study, three main findings were generated: first, Tf-
conjugated SPIO (Tf-SPIONs) is suitable for MR imaging;
secondly Tf-SPIONs could be specifically and efficiently internal-
ized by C6 glioma cells, along with prolonged retention and
detection by MR imaging; and thirdly Tf-SPIONs could create the
obvious contrast change of brain glioma in vivo following
administration of Tf-SPIONs owing to the larger accumulation
of Tf-SPIONs in the cytoplasm of brain glioma. Thus, the results
suggested that Tf-SPIONs could act as potential and specific MRI
targeting contrast agent for brain glioma, while possessing the
characteristics of long retention in glioma and higher T2
relaxation rate.
Characterization of Tf-SPIONs in physics is suitable for an
MRI contrast agent. Tf-SPIONs average particle size was
Figure 2. TEM image of SPIONs (Fig. 2a) and Tf-SPIONs (Fig. 2b), respectively.
doi:10.1371/journal.pone.0037376.g002
Figure 3. Magnetic properties of nanoparticles. (a) MR T2-
weighted images of SPIONs and Tf-SPIONs; (b) T2 relaxation rate (1/T2,
S
21) of SPIONs and Tf-SPIONs.
doi:10.1371/journal.pone.0037376.g003
Figure 4. Iron uptake in C6 cells treated with nanoparticles. (a)
In vitro T2-weighted MR. imaging of C6 cells with Tf-SPIONs. Under
0 mg/ml column: C6 cells only without SPIONs or Tf-SPIONs; SPIONs row:
C6 cells with SPIONs; Tf-SPIONs row: C6 cells with Tf-SPIONs. (b) Uptake
curves of C6 cells incubated with SPIONs or Tf-SPIONs.
doi:10.1371/journal.pone.0037376.g004
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provide favorable in vivo pharmacodynamic properties and
cellular uptake. R2, the relaxation rate, reflects the degree of the
MRI contrast agent on T2 relaxation rate. When the paramag-
netic nanoparticle T2 relaxation rate is higher, its ability to shorten
proton relaxation time is stronger and the MRI signal contrast
between tissues becomes more obvious. Hence, this kind of
nanoparticle is more suitable for use as negative MRI contrast
agent [21]. The MRI results indicated that the T2 relaxation rate
of Tf-SPIONs was 64.3 S
21 mM
21,thus being higher than that of
MRI contrast agent Combidex H (53.1 S
21 mM
21), which was
used in clinical studies for the detection of lymph node metastasis
[22]. Therefore, these results indicated that Tf-SPIONs with its
higher T2 relaxation rate, could be used as MRI contrast agent.
Previous studies demonstrated that SPIONs absorbed by glioma
cells in vitro is concentration dependent [23], and our study
corresponded to those observations. As shown in Figure 4a, C6
cells incubated with various concentrations of SPIONs or Tf-
SPIONs could induce signal intensity decrease. With increasing
concentrations, the signal intensity decreased more obviously.
Moreover, our study revealed that Tf-SPIONs incubated cells
displayed significantly negative contrast enhancement on T2-
weighted imaging at the respective nanoparticle concentrations,
which was in contrast to the cells incubated with SPIONs.
The intracellular uptake of nanoparticles results are consistent
with the signal enhancement observed in the cells incubated with
the nanoparticles on MRI. Larger degree of internalization of Tf-
SPIONs by C6 cells rather than that of SPIONs, suggested that
the increase of cellular uptake was most probably due to the
conjugation with Tf. Prussian blue staining provided further
evidence that large quantity of Tf-SPIONs accumulated in the
cytoplasm of C6 cells as shown in Figure 5; whereas relatively
smaller amounts of SPIONs were observed. These findings
demonstrate that Tf-SPION has high specificity for C6 glioma
cells, as well as high efficiency.
A 3.0 T MR scanner was utilized, to analyse the ability of Tf-
SPION to act as a contrast agent for brain glioma in vivo and
without saturation of the TfRs on BBB. As shown in Figure 6,
significant enhancement of brain glioma was observed with Tf-
SPIONs accumulating in tumor tissues, and possessing reasonable
signal level, as well as long retention in tumor center up to 48 h
post-injection. On the other hand, we observed low tumor uptake
and not much contrast change of the tumor before and after
administration of SPIONs. The result of Prussian blue staining
demonstrated further that Tf-SPIONs could get specifically
assembled into tumor tissues in vivo, which was consistent with
the MR imaging. As shown in Figure 7, Tf-SPIONs accumulating
in glioma was significantly higher than that of SPIONs. As for
SPIONs, the majority of nanopartilces were probably trapped by
the basement membrane and only a few of them could leak into
the periphery of glioma area by the increased vascular perme-
ability [12,23]. In addition, Muldoon et al suggested that Feridex
may remain in the basement membrane rather than pass through
incompetent BBB into the brain [24]. In our study, no significant
signal change was observed in tumor after injection of SPIONs
probably due to most of them being trapped by the basement
membrane. Recently, Gao HL et al compared the brain uptake of
Tf-conjugated polymersomes with that of lactoferrin [25]. The
results showed that Tf was more effective than lactoferrin in brain
targeting. This suggests that TfR on the BBB may be involved in
Tf transport across the BBB. Therefore, through receptor-
mediated endocytosis, Tf could cross the BBB and undergo
uptake by tumor cells.
In our previous study, the Lf receptor was expressed on the
glioma [12], but to the best of our knowledge, the Lf receptor
monoclonal antibody has not yet been found. In addtion, although
the Tf receptor monoclonal antibody (OX26) has good specificity,
Figure 5. C6 cells were stained with Prussian blue. (a):C6 cells only; (b):C6 cells incubated with Tf-SPIONs ; (c):C6 cells incubated with SPIONs.
doi:10.1371/journal.pone.0037376.g005
Figure 6. In vivo T2-weighted MR images of rats’ brain bearing
C6 gliomas. Upper row: acquired after administration of SPIONs
(12 mg/kg); lower row: acquired after administration of Tf-SPIONs
(12 mg/kg). The tumor was marked by yellow circle. After injection of
Tf-SPIONs, the changing area of decreased MR signal intensity increased
gradually with timing up to 48 h in comparison to the preinjection
image of tumor.
doi:10.1371/journal.pone.0037376.g006
Figure 7. Histochemical analysis of the tumor tissue. Rats were
sacrificed after 48 h of injection of nanoparticles. (a): sections were
stained with Prussian blue with SPIONs (4006); (b):with Tf-SPIONs
(4006).
doi:10.1371/journal.pone.0037376.g007
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further application of OX26. Alternatively, Tf is cheap and is easy
to prepare, and thereby Tf stands great potential for the clinical
application.
The biocompatibility of SPIONs is one of the most important
concerns in vivo application. Bourrinet et al. found that no
treatment-related clinical signs were observed for rats injected with
2, 13 or 40 mg/kg of Ferumoxtran-10, while rats receiving 126
and 400 mg/kg showed clinical symptoms associated with toxicity
[26]. Chertok et al. used 12 mg/kg of SPIONs as a drug carrier
for the treatment of rat glioma, the result of which showed that no
toxic effects were observed on the body [27]. In our study, we used
12 mg/kg of Tf-SPIONs, which was far less than the dose
reporting toxic reactions in rats. SPIONs conjugated with the
targeting ligand demonstrated the ability to be selectively uptaken
by target tissue and accordingly reduce the toxicity to other tissues
and organs. At present, improving site specific distribution, while
at the same time reducing spread to other tissues is the keypoint in
brain drug delivery sytem [25]. Considering this fact, it is
noteworthy that Tf-SPIONs utilized in imaging for glioma in rats
basically do not produce toxic effects, nevertheless their tissue
distribution requires further study.
Although the probes reported here support the potential use of
Tf-SPIONs for brain glioma imaging, significant work is required
to improve the probes. For instance, improvement of the probes
for the detection of the peripheral tumor or tumor cells within the
surrounding edema. The work presented here with Tf-SPIONs
serves as the foundation for future studies of targeted glioma
imaging and broad applications of MR imaging other tumors with
overexpressed Tf receptors as well as assessment of the recurrent
tumor after tumor resection and postoperative radiotherapy.
Materials and Methods
Synthesis and Characterization of Tf-SPIONs
Transferrin (Tf) from human transferrin was purchased from
Sigma-Aldrich (St. Louis, Mo, USA). Rats (male Wistar, 250–
300 g) were provided by Hubei center for Disease Control and
Prevention.
Tf-SPIONs was synthesized through EDC conjugation, follow-
ing the method in our previous report [12].
The formation of Tf-SPIONs was verified by fourier transform
infrared spectroscopy (FTIR, VERTEX 70, Bruker, Ettlingen,
Germany). For each sample, 2 mg of dried nanoparticles was
mixed with 200 mg of KBr and pressed into a pellet for analysis.
The morphology and size distribution of nanoparticles were
examined by transmission electron microscopy (TEM, JEM-2010,
JEOL, Tokyo, Japan) at 200 kV. The particle size was quantified
through a visual analysis of -200 particles in the TEM
micrographs.
The MR T2 relaxivity of the nanoparticles were determined
using 3.0-T whole body MR scanner (MAGNETOM Trio, A Tim
System 3T, Siemens, Munich, Germany) in combination with 8-
channel wrist joint coil. The particles were diluted in distilled
water, with iron concentrations in the range of 0–20 mg/mL.
Samples were transferred to a 96-well plate. T2-weighted images
were acquired using a multi-slice spin echo sequence. The
parameters were set as follows: field of view (FOV) 120 mm, base
resolution, 3846384, slice thickness 1.5 mm, multiple echo times
(TE) 20, 40, 60, 80,100,120,140 ms, repetition time (TR) 2000 ms,
and scan time was 13–14 min. T2 relaxation rates were plotted
against the iron concentrations in the particle dilutions. The
relaxivity was determined by a linear fit.
In vitro Study
C6 rat glioma cells were provided by the Institute of
Biochemistry and Cell Biology of Tongji Medical School (Wuhan,
China) [28]. Cells were cultured in Dulbecco modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum (Gibco,
USA) and antibiotics penicillin (100 IU/mL)/streptomycin
(100 mg/mL) in a humidified atmosphere with 5% CO2 at 37uC.
C6 Cells were incubated with SPIONs and Tf-SPIONs with
different iron concentrations (5, 10, 15 and 20 mg/mL) at 37uC
for 0.5 h. The cells were washed and then suspended by 300 mL
0.5% agarose gel. Samples were then quickly transferred to a 96-
well plate. MR imaging was performed on a 3.0-T magnet
(MAGNETOM Trio, A Tim System 3T, Siemens, Munich,
Germany). T2-weighted spin echo multi-slice pulse sequence was
used. The parameters were as following: field of view (FOV)
120 mm, base resolution, 3846384, slice thickness 1.5 mm,
multiple echo times (TE) 20, 40, 60, 80,100,120,140 ms, repetition
time (TR) 2000 ms, and scan time was 13–14 min.
C6 Cells were cultured with various nanoparticles at different
iron concentrations in the range of 0–20 mg/mL for 0.5 h at
37uC. The cells were washed and collected. Intracellular iron
content was determined by fast sequential atomic absorption
spectrometer (Spectr AA240FS, Varian, Palo Alto, USA). Cells
were added to 0.5 mL of perchloric acid and 2 mL nitric acid.
The mixtures were heated for 1 h and then cooled down to room
temperature. 2 mL distilled water was used to wash inner wall of a
conical flask and was then transferred to a centrifuge tube for
measurement. The parameter of Spectr AA240FS is following:
Wavelength, 248.3 nm; Slit, 0.2 nm; Lamp current, 5 mA;
Maximum Ash, 800uC; Atomize, 2300uC; Characteristic Mass, 2.
Untreated cells were seeded onto 6-well plates at a density of
2610
6 cells/well. 24 h following seeding, C6 glioma cells were
incubated with Tf-SPIONs and SPIONs at a concentration of
20 mg/mL for 2 h. C6 glioma cells were treated with PBS as the
control. After labeling, the samples were washed thrice with cell
culture medium and thrice with PBS. The cells were soaked with
4% paraform and washed with PBS, followed by staining with
Prussian Blue solution (equal volume of 6% hydrochloric acid and
2% potassium ferrocyanide) for 30 min. Afterwards, the treated
cells were counterstained with Nuclear Fast Red solution for
5 min. The samples were then examined and mounted under
optical microscope. The percentage of Prussian blue stained-
positive cells was counted under a random field of view (2006) and
the procedure was repeated 10 times for each sample.
In vivo Study
All animal experiments were approved by the Institutional
Animal Care and Use Committee at Union Hospital in the
Huazhong University of Science and Technology. Sixteen male
wistar rats were anesthetized with 10% Chloral Hydrate (i.p.,
100 g/0.4 mL) and immobilized in a stereotactic frame. A 1-mm
diameter burr hole was drilled through the skull 1 mm posterior
and 3.0 mm lateral to the bregma. A 20 ml micro- injector was
then used to inject 10 ml of the C6 cell suspension (1610
6 C6 cells
in DMEM). The injection was done slowly over 10 min,
maintained for 10 min and the needle was withdrawn after
another 10 min. The burr hole was filled with bone wax to prevent
extracerebral extension of the tumor and the skin was closed with
nonmagnetic sutures. MRI was performed on eight tumor bearing
rats administered with SPIONs via their tail veins, and on the
other eight tumor bearing rats which were injected with Tf-
SPIONs via the same route.
Rats were injected with 12 mg/kg body weight nanoparticles
via tail vein, following anesthesia. 8-channel wrist joint coil was
Tf-SPIONs for Brain Glioma Imaging
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37376used for MRI after the rats were placed in the imaging chamber.
The time course of nanoparticle distribution in the rat brain was
monitored by T2-weighted spin echo sequence. The parameter
were as following: field of view (FOV) 80 mm, base resolution,
1926192, slice thickness 1 mm, echo time (TE) 91 ms, repetition
time (TR) 6540 ms. The signal intensity of tumor was obtained at
the region of interest (ROI) of 2 mm
2, placed at the tumor site in
the same slice on T2WI, before and after the administration of
contrast agent such as Tf-SPIONs or SPIONs. The signal change
of the tumor was calculated using the following formula: (SIpre-
SIpost)/SIpre6100%, where SIpre and SIpost were the signal
intensity of tumor before and after the administration of contrast
agent.
Histological analysis of brain tissues was performed two days
post-injection. Rats were perfused with 250 mL Sodium Chloride
and 250 mL 4% paraform, brain tissues were removed and fixed
in 4% paraform for at least 24 h. The paraform fixed sections were
then embedded in paraffin and sectioned. Sections were subse-
quently stained with H&E and Prussian Blue per standard clinical
laboratory protocol.
Statistical analysis
The data were presented as mean 6 SE.
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